UBS Group AG Has $5.13 Million Position in Viridian Therapeutics, Inc. $VRDN

UBS Group AG reduced its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 63.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 164,820 shares of the company’s stock after selling 282,857 shares during the period. UBS Group AG’s holdings in Viridian Therapeutics were worth $5,129,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the business. US Bancorp DE boosted its position in shares of Viridian Therapeutics by 23.2% in the third quarter. US Bancorp DE now owns 2,457 shares of the company’s stock valued at $53,000 after acquiring an additional 463 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Viridian Therapeutics by 1.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock worth $669,000 after acquiring an additional 876 shares during the period. Sei Investments Co. increased its position in Viridian Therapeutics by 10.0% during the third quarter. Sei Investments Co. now owns 11,556 shares of the company’s stock worth $249,000 after acquiring an additional 1,046 shares during the period. Knights of Columbus Asset Advisors LLC increased its position in Viridian Therapeutics by 2.4% during the third quarter. Knights of Columbus Asset Advisors LLC now owns 59,410 shares of the company’s stock worth $1,282,000 after acquiring an additional 1,386 shares during the period. Finally, Arizona State Retirement System increased its position in Viridian Therapeutics by 8.7% during the fourth quarter. Arizona State Retirement System now owns 18,324 shares of the company’s stock worth $570,000 after acquiring an additional 1,460 shares during the period.

Insiders Place Their Bets

In related news, Director Fairmount Funds Management Llc acquired 1,176,470 shares of the company’s stock in a transaction on Monday, May 11th. The stock was purchased at an average cost of $17.00 per share, with a total value of $19,999,990.00. Following the acquisition, the director directly owned 5,090,928 shares of the company’s stock, valued at approximately $86,545,776. The trade was a 30.05% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.40% of the stock is owned by corporate insiders.

Viridian Therapeutics Price Performance

Shares of NASDAQ VRDN opened at $17.69 on Friday. The stock has a market capitalization of $1.82 billion, a PE ratio of -5.33 and a beta of 0.82. The company has a debt-to-equity ratio of 0.10, a current ratio of 15.15 and a quick ratio of 15.15. The business has a fifty day moving average price of $19.08 and a two-hundred day moving average price of $26.51. Viridian Therapeutics, Inc. has a fifty-two week low of $13.18 and a fifty-two week high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.90) earnings per share for the quarter, beating the consensus estimate of ($1.06) by $0.16. The firm had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $0.04 million. Viridian Therapeutics had a negative return on equity of 80.19% and a negative net margin of 490.31%.The company’s quarterly revenue was up 95.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.87) EPS. As a group, equities analysts predict that Viridian Therapeutics, Inc. will post -3.71 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on VRDN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Viridian Therapeutics in a research report on Monday, April 20th. Wedbush lowered their price target on shares of Viridian Therapeutics from $37.00 to $31.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, May 5th. Stifel Nicolaus set a $39.00 price objective on Viridian Therapeutics in a report on Wednesday, May 13th. Finally, Royal Bank Of Canada lifted their price objective on Viridian Therapeutics from $30.00 to $34.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $36.14.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.